Latest News Archive

Please select Category, Year, and then Month to display items

UFS expert to attend the WHO Traditional Medicine G20 Health Ministers Global Summit

04 May 2023 | Story Andre Damons | Photo Supplied

Prof Matsabisa Motlalepula, an African traditional medicine expert from the University of the Free State (UFS), will attend the first World Health Organisation (WHO) Traditional Medicine Global Summit in India in August after being invited to serve as a member of the Summit External Advisory Group for the WHO Traditional Medicine Global Summit (“Advisory Group”).

As chairperson of the WHO Regional Expert Advisory Committee on Traditional Medicine (REACT), Prof Motlalepula, the Director of the UFS Department of Pharmacology, has been nominated to serve as the Global Summit Advisory Group expert from the WHO to provide advice on themes, content, and format of sessions, and to provide reviews and recommendations to the Summit session coordinators and speakers at the Summit.

Summit will highlight success stories

The Advisory Group is comprised of nine members nominated across the six WHO regions and globally, with recognised expertise in traditional medicines as well as expertise on the Summit focus areas that include leadership and partnership, evidence and learning, data and regulation, biodiversity and sustainability, innovation and technology.

WHO will hold its Traditional Medicine Global Summit from August 17-18, 2023, in Gandhinagar, Gujarat, India, alongside the G20 health ministerial meeting. The Summit will be organised by the WHO Global Centre for Traditional Medicine collaborating closely with all WHO major offices.

The Summit will highlight success stories in countries using traditional medicine across universal health coverage, the Sustainable Development Goals (SDGs), and Health for All. It will showcase game-changing advances in evidence, data, biodiversity and innovations that enable the safe, effective and equitable use of traditional medicine. The Summit will be a platform for all stakeholders of traditional medicine, including policymakers, practitioners, academics, private sector, civil society, community representatives, and others will discuss health and traditional medicines issues.

WHO expert

“It is always an honour and privilege for me to be asked to avail myself to the activities of such high-level United Nations bodies. I am humbled to be identified and nominated by WHO to be amongst the nine experts in the six WHO regions and globally.

“I am very honoured and will do my utmost to deliver on the global mandate as well as stick to the terms of reference of my appointment to such a prestigious global summit. This shows the trust the WHO has in my capabilities, and this is good for the institution, the continent as well as the traditional health practitioners and scientists in this field of research,” says Prof Motlalepula.

Endorsing well-researched traditional medicines

He says each time he sees the involvement of Africa in these international gatherings on traditional medicines, it marks another step toward the institutionalisation and global acceptance of African traditional medicines and medical practices in health systems. It further shows the growing role UFS is beginning to play in the global arena around traditional medicines.

According to him, he will, as always, push for WHO to be an example in support of traditional medicines and the participation of traditional health practitioners in its activities.

“I would seek from WHO to look into endorsing well-researched traditional medicine products and making them available in our health systems. Secondly, making recommendations for review of medicines regulatory authorities to reform and look favourably at traditional medicines product registration systems. I would advise on supporting continuous research into traditional medicines but more importantly for those products to be registered and put on the market.”

Prof Motlalepula says he has a few expectations, always working hard, dedicating his time and efforts to delivering what is expected, being part of a team and contributing to the overall team efforts. He expects positive resolutions moving forward the development and institutionalisation of traditional medicines, as well as a commitment to see the acceptance that the contribution of traditional medicines plays in the well-being of people and its formal contributions to universal health coverage and SDGs acknowledged.

“I expect to hear about improved financial and political support for research and fast-tracking the manufacturing of well-researched, quality, safe and effective traditional medicines and their inclusion in national health systems. I expect to hear talk about integrated health that incorporates the application of traditional medicines in national health systems. I expect indeed a few positive things around the development of traditional medicine and serious commitment to supporting it.

“Given the scope of the work of the Advisory Group, it is very clear that the work is huge for the organisation, but I am ready for this,” says Prof Motlalepula.

The scope of work for the Advisory Group has been prepared and includes:

Providing expert advice to WHO on the technical content and format of the sessions and exhibition for the WHO Traditional Medicine Global Summit;
Agreeing on technical review criteria with respect to thematic coherence across the Summit, strength of evidence and data, methodologies, global relevance and other considerations;
Reviewing the proposed content of the Summit sessions and exhibitions using the technical review criteria and providing expert recommendations to ensure high-quality sessions;
Advising on the development of a journal series of papers related to the Global Summit using the agreed technical criteria to select the papers;
Providing expert inputs to Summit organisation meetings and multistakeholder consultations, as agreed with WHO;
Developing and sharing recommendations of the Summit advisory group with WHO and partners in a timely manner to inform the organisation of the Summit, as appropriate in alignment with the WHO conflict-of-interest declaration and Framework for Engagement with Non-State Actors (FENSA); and
Developing an Advisory Group report advising WHO on key lessons and priority actions following the first WHO Traditional Medicine Global Summit.

News Archive

Stem cell research and human cloning: legal and ethical focal points

2004-07-29

(Summary of the inaugural lecture of Prof Hennie Oosthuizen, from the Department of Criminal and Medical Law at the Faculty of Law of the University of the Free State.)

In the light of stem cell research, research on embryo’s and human cloning it will be fatal for legal advisors and researchers in South Africa to ignore the benefits that new bio-medical development, through research, contain for this country.

Legal advisors across the world have various views on stem cell research and human cloning. In the USA there is no legislation that regulates stem cell research but a number of States adopted legislation that approves stem cell research. The British Parlement gave permission for research on embryonic stem cells, but determined that it must be monitored closely and the European Union is of the opinion that it will open a door for race purification and commercial exploitation of human beings.

In South Africa the Bill on National Health makes provision for therapeutical and non therapeutical research. It also makes provision for therapeutical embryonical stem cell research on fetuses, which is not older than 14 days, as well as for therapeutical cloning under certain circumstances subject to the approval of the Minister. The Bill prohibits reproductive cloning.

Research on human embrio’s is a very controversial issue, here and in the rest of the world.

Researchers believe that the use of stem cell therapy could help to side-step the rejection of newly transplanted organs and tissue and if a bank for stem cell could be built, the shortage of organs for transplants would become something of the past. Stem cells could also be used for healing of Alzheimer’s, Parkinson’s and spinal injuries.

Sources from which stem cells are obtained could also lead to further ethical issues. Stem cells are harvested from mature human cells and embryonic stem cells. Another source to be utilised is to take egg cells from the ovaries of aborted fetuses. This will be morally unacceptable for those against abortions. Linking a financial incentive to that could become more of a controversial issue because the woman’s decision to abort could be influenced. The ideal would be to rather use human fetus tissue from spontaneous abortions or extra-uterine pregnancies than induced abortions.

The potential to obtain stem cells from the blood of the umbilical cord, bone-marrow and fetus tissue and for these cells to arrange themselves is known for quite some time. Blood from the umbilical cord contains many stem cells, which is the origin of the body’s immune and blood system. It is beneficial to bank the blood of a newborn baby’s umbilical cord. Through stem cell transplants the baby or another family member’s life could be saved from future illnesses such as anemia, leukemia and metabolic storing disabilities as well as certain generic immuno disabilities.

The possibility to withdraw stem cells from human embrio’s and to grow them is more useable because it has more treatment possibilities.

With the birth of Dolly the sheep, communities strongly expressed their concern about the possibility that a new cloning technique such as the replacement of the core of a cell will be used in human reproduction. Embryonic splitting and core replacement are two well known techniques that are associated with the cloning process.

I differentiate between reproductive cloning – to create a cloned human embryo with the aim to bring about a pregnancy of a child that is identical to another individual – and therapeutically cloning – to create a cloned human embryo for research purposes and for healing human illnesses.

Worldwide people are debating whether to proceed with therapeutical cloning. There are people for and against it. The biggest ethical objection against therapeutical cloning is the termination of the development of a potential human being.

Children born from cloning will differ from each other. Factors such as the uterus environment and the environment in which the child is growing up will play a role. Cloning create unique children that will grow up to be unique individuals, just like me and you that will develop into a person, just like you and me. If we understand this scientific fact, most arguments against human cloning will disappear.

Infertility can be treated through in vitro conception. This process does not work for everyone. For some cloning is a revolutionary treatment method because it is the only method that does not require patients to produce sperm and egg cells. The same arguments that were used against in vitro conception in the past are now being used against cloning. It is years later and in vitro cloning is generally applied and accepted by society. I am of the opinion that the same will happen with regard to human cloning.

There is an argument that cloning must be prohibited because it is unsafe. Distorted ideas in this regard were proven wrong. Are these distorted ideas justified to question the safety of cloning and the cloning process you may ask. The answer, according to me, is a definite no. Human cloning does have many advantages. That includes assistance with infertility, prevention of Down Syndrome and recovery from leukemia.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept